Evidence review
Zepbound and Wegovy Clinical Trial Results: Who Was Studied and How Much Weight They Lost
Sample sizes, who was enrolled and average weight loss in each Zepbound and Wegovy weight trial, taken from the current FDA labels.
On this page
In their main weight trials, adults without diabetes lost an average of about 15% of body weight on Wegovy 2.4 mg over 68 weeks and about 21% on Zepbound 15 mg over 72 weeks, against roughly 2% to 3% on placebo. Both drugs did less in people with type 2 diabetes. The tables below give every weight trial on each label: how many people took part, who they were, and what happened, so you can look past the headline figure.1, 2
All figures come from the current U.S. prescribing information, read on November 20, 2026: Zepbound's label revised November 2026 and Wegovy's revised June 2026. Results are the labels' intention-to-treat averages, which count everyone randomized, including people who stopped the drug. They are averages, and individual results varied widely; they also describe the brand products only.
Zepbound (tirzepatide)
In Zepbound's first two weight trials, everyone received a reduced-calorie diet and exercise counseling alongside the drug or placebo, and doses rose over up to 20 weeks before at least 52 weeks on the maintenance dose.1
Scroll to compare all columns.
| Trial | Who took part | Result at the end |
|---|---|---|
| Study 1, 72 weeks | 2,539 adults with obesity, or overweight plus a weight-related condition; no diabetes. Average age 45, 68% women, 104.8 kg | Weight change: placebo -3.1%; 5 mg -15.0%; 10 mg -19.5%; 15 mg -20.9% |
| Study 2, 72 weeks | 938 adults with type 2 diabetes and a BMI of 27 or more. Average age 54, 51% women, 100.7 kg | Placebo -3.2%; 10 mg -12.8%; 15 mg -14.7% |
| Study 3, 84 weeks | 806 adults began a 12-week intensive lifestyle program; the 579 who lost at least 5% were randomized | From randomization: placebo +2.5%; highest tolerated dose -18.4% |
| Study 4, 88 weeks | 783 adults took Zepbound for 36 weeks (average loss 20.9%), then 670 were randomized to continue or switch to placebo | Over the next 52 weeks: placebo regained 14.0%; continuing lost a further 5.5% |
In Study 1, 34.5% of the placebo group lost at least 5% of their weight, against 85.1% to 90.9% on Zepbound depending on dose; on 15 mg, 56.7% lost at least 20%.1 Study 4 is the clearest evidence on stopping: people switched to placebo regained much of what they had lost, a pattern our weight-regain guide covers in more depth.
Zepbound is also approved for obstructive sleep apnea in adults with obesity. Two 52-week trials enrolled 469 people with moderate to severe sleep apnea, one group not using a breathing machine and one using one. The apnea-hypopnea index, the number of breathing interruptions per hour, fell by 25.3 and 29.3 events an hour on Zepbound, against 5.3 and 5.5 on placebo.1
Wegovy (semaglutide)
Wegovy's weight trials also combined the drug with diet and exercise counseling. Doses rose to 2.4 mg over about 16 weeks, or 20 weeks in the 7.2 mg trials.2
Scroll to compare all columns.
| Trial | Who took part | Result at the end |
|---|---|---|
| Study 2, 68 weeks | 1,961 adults with obesity, or overweight plus a weight-related condition; no diabetes. Average age 46, 74% women, 105.3 kg | Placebo -2.4%; 2.4 mg -14.9% |
| Study 3, 68 weeks | 807 adults with type 2 diabetes and a BMI of 27 or more. Average age 55, 51% women | Placebo -3.4%; 2.4 mg -9.6% |
| Study 4, 68 weeks | 611 adults without diabetes, starting with an 8-week low-calorie diet and a structured exercise program | Placebo -5.7%; 2.4 mg -16% |
| Study 6, 68 weeks | 401 adults in Japan and South Korea; 63% men, 24.7% with type 2 diabetes | Placebo -2.1%; 1.7 mg -9.6%; 2.4 mg -13.2% |
| Study 7, 64 weeks | 307 adults without diabetes, taking the daily 25 mg tablet | Placebo -2.4%; tablet -13.6% |
| Study 8, 72 weeks | 1,407 adults with obesity, without diabetes. Average 113 kg | Placebo -3.9%; 2.4 mg -15.5%; 7.2 mg -18.8% |
| Study 9, 72 weeks | 512 adults with obesity and type 2 diabetes | Placebo -3.8%; 2.4 mg -10.4%; 7.2 mg -13.2% |
Wegovy's Study 5 was a withdrawal trial: of 902 people who started, the 803 who reached 2.4 mg after 20 weeks were randomized to continue or switch to placebo. Over the next 48 weeks, those switched gained 6.9% while those continuing lost a further 7.9%.2 In adolescents aged 12 and over (Study 10, 201 participants), the main measure was body-mass index, which fell 16.1% on Wegovy and rose 0.6% on placebo.2 The label's Study 1 is a cardiovascular-outcomes trial rather than a weight trial, and our side-effects guide covers what the trials recorded about adverse effects.
How to read these numbers
The populations matter. Both drugs produced smaller average losses in people with type 2 diabetes, and in the largest trial of each drug about seven in ten participants were women and the average starting weight was above 100 kg. Trials also ran for a fixed period with lifestyle counseling and close follow-up, which a telehealth subscription may not match.
Head-to-head, the label numbers are not a direct comparison: the trials enrolled different people at different times. Our Mounjaro and Zepbound comparison and semaglutide versus tirzepatide page cover how the two molecules compare, and the research library collects the other evidence pages.
None of these trials tested a compounded preparation. The results belong to Zepbound and Wegovy as manufactured; the compounded versus brand guide explains why they cannot be carried over to a pharmacy's vial. If you are weighing cost against these results, the tirzepatide cost page shows current prices on both routes.
Frequently asked questions
How many people were in Zepbound's clinical trials?
Its first weight trial enrolled 2,539 adults without diabetes and its second 938 adults with type 2 diabetes. Two further weight trials enrolled 806 and 783 people, and two sleep apnea trials 469 in total.
How much weight did people lose on Wegovy in trials?
In the main 68-week trial of adults without diabetes, the average was 14.9% on Wegovy 2.4 mg against 2.4% on placebo. On the higher 7.2 mg dose, a 72-week trial reported 18.8%.
Who was in the Zepbound trials?
In Study 1, the average participant was 45 years old with a weight of 104.8 kg, and 68% were women. People with type 2 diabetes were studied separately in Study 2.
Do these results apply to compounded tirzepatide or semaglutide?
No. The trials tested the brand products. No equivalent trial exists for any individual pharmacy's compounded preparation.
References
- Eli Lilly and Company (2026). Zepbound U.S. prescribing information, revised November 2026, section 14. Eli Lilly and Company. Read source
- Novo Nordisk (2026). Wegovy prescribing information, revised June 2026, sections 14.2 and 14.3. Novo Nordisk. Read source
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Continue reading
Do You Need Blood Tests Before Starting a GLP-1?
What Wegovy and Zepbound labels say about glucose, kidney and thyroid checks, plus the follow-up and lab-cost questions to ask a GLP-1 provider.
ReadMounjaro vs. Zepbound: Uses, Ages and Dose Limits
Compare Mounjaro and Zepbound uses, age limits and maintenance doses using current labels and trials. Shared tirzepatide does not make labels identical.
ReadZepbound and CPAP: What the Trials Cannot Decide
Separate Zepbound’s OSA trial results from the unresolved decision about ending PAP, including temporary research withdrawal and residual disease.
ReadCompounded Tirzepatide vs. Zepbound, and Compounded Semaglutide vs. Wegovy: What Actually Differs
Is compounded tirzepatide the same as Zepbound? The molecule can match; approval, formulation, additives like B12, evidence and price do not.
ReadHow to Dispose of GLP-1 Pens and Needles
Follow device-specific US guidance for Ozempic, Wegovy and Zepbound KwikPen, then choose a sharps container and confirm local disposal.
ReadGLP-1 Prior Authorization Denied: Appeal, Correct the Request or Pay Cash?
Read a Wegovy or Zepbound denial, distinguish missing records from exclusions, check appeal deadlines and compare cash costs without giving up too soon.
Read